ob/ob Mouse Model of Obesity and Diabetes

Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic

Type II diabetes is characterized by high blood glucose levels, insulin resistance, ß-cell loss, as well as a predisposition towards obesity and dyslipidemia. While there are many animal models of type II diabetes that demonstrate impaired glucose challenge (see OGTT mouse model), the ob/ob mice model is a well-accepted model of type II diabetes that recapitulates many aspects of type II diabetes in humans.

Ob/ob mice express mutations in the leptin gene that lead to obesity.  These mice display progressive food intake, insulin resistance and moderately increased blood glucose levels.  This strain can be used to model prediabetes, and early phases of diabetes and obesity.  Melior uses this model to evaluate test compound’s ability to treat the above-mentioned conditions.

Blood glucose level in rosiglitazone or vehicle-treated ob/ob mice following glucose challenge.

The graph illustrates the difference in response to a blood glucose challenge in ob/ob mice treated with vehicle or rosiglitazone – an insulin sensitizer and antidiabetic drug. Ob/ob mice administered rosiglitazone show significantly lower blood glucose across time relative to vehicle treated mice. Data are mean ± SEM; * p<0.05, **p<0.01 compared to vehicle (N=4-7).

The ob/ob mouse model may be used in an acute setting but is more typically used in a chronic setting to evaluate a compound’s cumulative action over several weeks of treatment. The variability if reasonably low such that good statistically significant effects are seen with validating compounds with group sizes of about 8 animals.